酒石酸伐尼克兰片用于成人戒烟。伐尼克兰是烟碱型乙酰胆碱受体 α4β2 亚 型的选择性部分激动剂，对神经中该受体具有高度亲和力。伐尼克兰与 α4β2 受 证券代码：301507 证券简称：民生健康 公告编号：2025-001 杭州民生健康药业股份有限公司 关于公司取得酒石酸伐尼克兰片药品批文的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 近日，杭州民生健康药业股份有限公司（以下简称"公司"）收到国家药品 监督管理局核准签发的酒石酸伐尼克兰片《药品补充申请批准通知书》，现将相 关情况公告如下： 一、药品的基本情况 药品名称：酒石酸伐尼克兰片 英文名/拉丁名：Varenicline Tartrate Tablets 通知书编号：2025B00553 主要成份：酒石酸伐尼克兰 剂型：片剂 规格：0.5mg（按 C13H13N3 计） 注册分类：化学药品 药品有效期：36 个月 药品批准文号：国药准字 H20233137 上市许可持有人：名称：杭州民生健康药业股份有限公司 地址：浙江省杭州市临平区东湖街道新天路 101 号 二、药品相关情况 杭州民生健康药 ...

证券代码：301507 证券简称：民生健康 公告编号：2024-060 杭州民生健康药业股份有限公司 关于与中科嘉亿等主体签署《战略合作协议》的 公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 特别提示： 1、杭州民生健康药业股份有限公司（以下简称"民生健康"或"公司"）拟通 过全资子公司民生中科嘉亿（浙江）生物工程有限公司（以下简称"民生中科（浙 江）"）收购民生中科嘉亿（山东）生物工程有限公司（以下简称"标的公司"） 现有股东持有的标的公司100%股权。即标的公司现有股东以其所持标的公司全部股 权增资民生中科（浙江），增资完成后，民生中科（浙江）注册资本增加至16,000万 元人民币，标的公司现有股东将合计持有民生中科（浙江）45%的股权。民生健康 拟放弃本次民生中科（浙江）增资扩股的优先认购权，放弃权利涉及的注册资本金 额为7,200万元人民币。 2、本次交易完成后，公司持有民生中科（浙江）的股权将由100%被稀释至55%， 民生中科（浙江）由公司全资子公司变更为控股子公司。标的公司成为民生中科（浙 江）的全资子公司并纳入公司的合并报表范围。 ...

证券代码：301507 证券简称：民生健康 公告编号：2024-059 杭州民生健康药业股份有限公司（以下简称"公司"）第二届董事会第六次 会议于2024年12月23日以现场及通讯方式召开，本次会议通知于2024年12月20日 以书面、通讯等方式发出。本次会议由竺福江先生召集并主持，应到董事9人， 实到董事9人，全体监事、高级管理人员列席会议。本次会议的召集、召开符合 《中华人民共和国公司法》（以下简称"《公司法》"）、《杭州民生健康药业股份有 限公司章程》（以下简称"《公司章程》"）以及有关法律、法规的有关规定，所作 决议合法有效。 杭州民生健康药业股份有限公司 二、董事会会议审议情况 （一）审议通过了《关于与中科嘉亿等主体签署<战略合作协议>的议案》 经审议，董事会认为：本合作协议的签署，将有利于拓展公司在益生菌领域 的业务发展空间，提升研发实力和市场竞争力，增强公司综合影响力，有助于进 一步提升公司的业务规模和盈利能力，符合公司长期发展战略、业务布局和全体 股东的利益。因此，董事会同意公司与中科嘉亿（山东）投资控股有限公司（简 称"中科嘉亿"）等主体签署《战略合作协议》，同意公司通过全资子公司民生中 科 ...

证券代码：301507 证券简称：民生健康 公告编号：2024-058 杭州民生健康药业股份有限公司 关于公司及全资子公司取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 一、取得发明专利的基本情况 专利权人：杭州民生健康药业股份有限公司 浙江民生健康科技有限公司 授权公告日：2024 年 12 月 20 日 专利权期限：二十年，自申请日起算 本发明专利涉及质控检测技术领域，具体涉及一种从维生素矿物质复合制剂 中提取维生素 K2 的提取液及提取方法。本专利技术能有效溶解维生素 K2 微囊 壁材，对维生素 K2 提取效果优异，能有效提高从维生素矿物质复合制剂中维生 素 K2 的质控检测准确度。本发明专利涉及的技术已经应用于公司现有产品的检 近日，杭州民生健康药业股份有限公司（以下简称"公司"）及公司全资子 公司民生中科嘉亿（浙江）生物工程有限公司（原浙江民生健康科技有限公司） 收到国家知识产权局颁发的一项发明专利证书，具体情况如下： 发明名称：一种从多种维生素矿物质复合制剂中提取维生素 K2 的提取液及 提取方法 证书号：第 7614 ...

Group 1: Company Overview - The company was established in 2009, spun off from the controlling shareholder, Minsheng Pharmaceutical, and formed a joint venture with Sanofi in 2010, which was fully acquired in 2017 [1] - The company focuses on dietary supplements, with the per capita consumption of such products in China being approximately 1/5 of that in developed countries [2] Group 2: Product Performance - The sales of the multi-dimensional element tablets (21) are expected to show steady growth, indicating a strong market potential [2] - The main growth driver in the health product category is the Vitamin and Mineral series, particularly the "21 Jinweita Peach Blossom Vase" targeted at adult women [2] Group 3: Market Strategy - The company is expanding its sales channels through the "21 Jinweita" brand, which includes online distribution and partnerships, impacting overall gross margins [2] - The company is focusing on building a comprehensive ecosystem in the probiotic sector through strategic partnerships [3] Group 4: Future Directions - Future product development will include probiotics, traditional health products, OTC drugs, and online distribution, aiming to enhance business scale and profitability [3] - The company is open to mergers and acquisitions in the health sector, aligning with its strategic development plans [3]

Summary of the Conference Call for Hangzhou Minsheng Health Pharmaceutical Co., Ltd. Company Overview - Hangzhou Minsheng Health Pharmaceutical Co., Ltd. focuses on the health sector, specializing in the research, production, and sales of vitamins, minerals, and other over-the-counter health food products [1] Financial Performance - For the fiscal year 2024, the company reported a revenue of 641 million yuan, representing a year-on-year increase of 10.23% [1] - The net profit attributable to shareholders was 91.83 million yuan, reflecting a growth of 7.24% compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 87.21 million yuan, which is a 10.13% increase year-on-year [1] Strategic Initiatives - The company aims to enhance product innovation and research by focusing on new products, new business models, and new projects as part of its core strategy for 2024 [2] - There is an emphasis on expanding the product matrix in the OTC health food sector, particularly in micro-mineral and other categories [2] Business Development - The company achieved a 15.7% increase in net profit for the first quarter of 2024, amounting to 6.3 million yuan, with a 6.5% growth compared to the same period last year [3] - The launch of the carbonic enzyme mixed solution in the OTC sector is highlighted as a significant achievement [3] - Strategic partnerships in the medical field are being pursued to accelerate growth and enhance resource integration [3] - New health brands, such as Minsheng Tongchun Medical Aesthetics, are being introduced alongside existing product lines [3] Future Outlook - The company plans to continue leveraging its "Four New" strategy to deepen its focus on micro-mineral therapeutic OTC medications and accelerate the launch of new products [4] - There is a commitment to continuously improve the product pipeline to support rapid growth in performance [4] - The management expresses a desire for feedback from investors and stakeholders to further enhance company operations [4]

Financial Performance - The company's revenue for Q3 2024 was CNY 122,412,416.08, representing a 3.65% increase year-over-year, while the year-to-date revenue reached CNY 519,847,972.13, up 6.98% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2024 was CNY 8,909,041.54, a decrease of 23.33% year-over-year, with year-to-date net profit at CNY 86,178,415.70, an increase of 5.52%[3]. - The basic earnings per share for Q3 2024 was CNY 0.02, down 50.00% year-over-year, while the diluted earnings per share also stood at CNY 0.02, reflecting the same decline[3]. - The net profit for Q3 2024 was CNY 86,178,415.70, an increase of 5.5% compared to CNY 81,672,290.77 in Q3 2023[23]. - Operating profit for Q3 2024 reached CNY 100,821,117.14, up from CNY 93,443,439.27 in the same period last year, reflecting a growth of 7.4%[23]. - The total comprehensive income for Q3 2024 was CNY 86,178,415.70, compared to CNY 81,672,290.77 in Q3 2023, indicating a growth of 5.5%[23]. Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to CNY 1,708,017,882.54, a 3.65% increase from the end of the previous year[3]. - The total equity attributable to shareholders increased to ¥1,523,583,194.28 from ¥1,473,060,211.58, reflecting a growth of approximately 3.4%[21]. - The company's cash and cash equivalents decreased to ¥389,824,520.26 from ¥428,301,750.63, a decline of approximately 9.5%[20]. Cash Flow - The company's cash flow from operating activities for the year-to-date period was CNY 101,039,367.62, showing a 20.81% increase compared to the same period last year[3]. - Cash flow from operating activities increased to CNY 101,039,367.62, compared to CNY 83,634,005.05 in Q3 2023, marking a growth of 20.8%[24]. - The company experienced an increase in cash inflows from operating activities, totaling CNY 603,654,399.05, compared to CNY 492,013,037.77 in the previous year[24]. - The net cash flow from investing activities was negative at CNY -102,836,717.85, primarily due to cash used for purchasing financial products[8]. - The company reported a net cash outflow from investing activities of CNY -102,836,717.85, compared to CNY -72,777,857.74 in Q3 2023[25]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,480, with the largest shareholder holding 66.75% of the shares[9]. - The company reported a total of 238,000,000 restricted shares at the beginning of the period, with no shares released during the period, maintaining the same number at the end[13]. - Zhejiang Puhua Tianqin Equity Investment Management Co., Ltd. holds 10,423,629 unrestricted shares, representing the largest shareholder[11]. - The top 10 unrestricted shareholders collectively hold 272,008,733 shares, with a significant portion held by Zhejiang Puhua Tianqin and Hangzhou Shobo Equity Investment[14]. - The total number of unrestricted shares held by the top 10 shareholders is 272,008,733, with Zhejiang Puhua Tianqin being the largest[11]. Strategic Initiatives - The company signed a strategic cooperation intention agreement in the probiotics field, aiming for resource sharing and enhancing market competitiveness[15]. - The strategic cooperation agreement is expected to enhance the company's business scale and profitability, although its impact on 2024 performance remains uncertain[15]. - The company’s market expansion strategy includes collaboration with partners in the probiotics sector, which aligns with its long-term development goals[15]. - The company approved a restricted stock incentive plan, granting 3,320,000 shares at a price of 6.67 CNY per share to 40 eligible participants[16]. - The company’s stock incentive plan was approved in September 2024, indicating a focus on employee motivation and retention[16]. Operational Metrics - Operating costs amounted to ¥429,009,479.08, up from ¥397,746,837.53, reflecting a rise in operating expenses[22]. - Research and development expenses were ¥21,522,017.88, slightly down from ¥22,898,659.93 in the previous period[22]. - Accounts receivable increased by 35.81% to CNY 46,458,110.58 due to higher revenue from core business operations[6]. - Accounts receivable rose to ¥46,458,110.58 from ¥34,207,790.42, showing a significant increase of 36%[20]. - Inventory decreased to ¥86,614,319.58 from ¥105,315,599.46, a reduction of about 17.7%[20].

证券代码：301507 证券简称：民生健康 公告编号：2024-056 杭州民生健康药业股份有限公司 关于开立募集资金现金管理专用 尽管公司选择安全性高、流动性好的投资品种，但金融市场受宏观经济的影 响较大，不排除该等投资受到市场波动的影响。 结算账户的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）于2024年4月22日召开 第一届董事会第十六次会议及第一届监事会第十二次会议，并于2024年5月17日 召开2023年年度股东大会，审议通过了《关于使用部分闲置募集资金（含超募资 金）进行现金管理的议案》，同意公司在不影响募集资金投资项目建设和公司正 常经营、不改变募集资金使用用途的前提下，使用最高不超过人民币7.5亿元的暂 时闲置募集资金（含超募资金）进行现金管理，单笔投资产品期限最长不超过12 个月，有效期自公司股东大会审议通过之日起12个月，公司可在上述额度及期限 内滚动使用投资额度。具体内容详见公司在巨潮资讯网（http://www.cninfo.com.cn） 披露的《关于使用部分闲置募集资金 ...

之 独立财务顾问报告 公司简称：民生健康 证券代码：301507 上海荣正企业咨询服务（集团）股份有限公司 关于 杭州民生健康药业股份有限公司 2024 年限制性股票激励计划 首次授予相关事项 3 二、声明 本独立财务顾问对本报告特做如下声明： （一）本独立财务顾问报告所依据的文件、材料由民生健康提供，本激励 计划所涉及的各方已向独立财务顾问保证：所提供的出具本独立财务顾问报告 所依据的所有文件和材料合法、真实、准确、完整、及时，不存在任何遗漏、 虚假或误导性陈述，并对其合法性、真实性、准确性、完整性、及时性负责。 本独立财务顾问不承担由此引起的任何风险责任。 （二）本独立财务顾问仅就本激励计划对民生健康股东是否公平、合理， 对股东的权益和上市公司持续经营的影响发表意见，不构成对民生健康的任何 投资建议，对投资者依据本报告所作出的任何投资决策而可能产生的风险，本 独立财务顾问均不承担责任。 2024 年 9 月 | | | | 一、释义 3 | | --- | | 二、声明 4 | | 三、基本假设 5 | | 四、独立财务顾问意见 6 | | （一）本次限制性股票激励计划的审批程序 6 | | （二）本次实 ...

一、会议召开情况 1、会议召开时间： 证券代码：301507 证券简称：民生健康 公告编号：2024-051 杭州民生健康药业股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会召开期间无变更、否决提案的情况； 2、本次股东大会未涉及变更前次股东大会决议的情况。 （1）现场会议召开时间：2024 年 9 月 18 日（星期三）下午 14:30。 （2）网络投票时间：通过深圳证券交易所互联网系统投票的时间为 2024 年 9 月 18 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易所交 易系统进行网络投票的时间为 2024 年 9 月 18 日上午 9:15 至下午 15:00 的任意 时间。 2、现场会议召开地点：杭州市西湖区曙光路 122 号。 3、会议召开方式：现场投票和网络投票相结合。 4、会议召集人：董事会。 5、会议主持人：董事长竺福江先生。 6、本次会议的召集、召开符合《中华人民共和国公司法》、《上市公司股东 大会规 ...